Navigation Links
Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
Date:10/1/2009

CHICAGO, Oct. 1 /PRNewswire-FirstCall/ -- The Female Health Company (FHC) (NASDAQ: FHCO) announced today that its second-generation FC2 Female Condom®, which received regulatory approval from the Food and Drug Administration in March as an HIV prevention method, is now available for purchase in the United States.

The company made the announcement in Atlanta at a meeting of the Southeastern Urban Initiative for Reproductive Health, a coalition of reproductive health advocates from Southern states that is advocating for increased federal funding for HIV prevention.

"America's HIV epidemic isn't going away. In fact, it's getting worse, and African American and Latino women are disproportionately impacted," said Dazon Dixon Diallo, Founder and President of SisterLove, a grassroots service organization that supports HIV/AIDS prevention and reproductive health programs for women in the Atlanta, Georgia region. "It's time to provide women in heavily impacted communities with expanded access to affordable women-controlled options, and the female condom becomes that choice. Women will use it if they have it."

"We're thrilled that FC2 is now available in the United States," said Mary Ann Leeper, FHC's senior strategic adviser, who will deliver a keynote address on the female condom and woman-initiated prevention at the Atlanta meeting. "We developed the female condom to provide women with access to HIV prevention that they can initiate. We know that women and men practice safer sex when they have access to more prevention methods, and we believe that access to the female condom can help millions of American women negotiate safer sex with their partners."

FC2 may be purchased from the Company's two public sector distributors: Total Access Group, Inc. www.totalaccessgroup.com and Global Protection Corporation, www.globalprotection.com/store. In addition, FHC has launched a website, www.fc2femalecondom.com, which includes tiered pricing information for ordering a minimum quantity of 25,000 units directly from the Company. Price per unit declines based on the volume purchased. It is important to note that the maximum price to purchase FC2 from the Company's distributors is $0.82/unit regardless of quantity, approximately a 30% decrease from the price paid for FC1.

FHC Makes Commitment to Expanded Access and Education

Seven of the top 10 states ranked by the rate of AIDS cases are in the U.S. South. FHC is initiating a program to work with a number of southern reproductive health service organizations to provide free allotments of FC2 Female Condoms as part of an introductory awareness and education program, including training for health providers on how to integrate female condom education into reproductive health counseling.

Data from the Centers for Disease Control and Prevention (CDC) show that women represent a growing proportion of Americans living with HIV and AIDS. Over the past two decades, the percentage of women among all people living with HIV in the U.S. has increased from 8 percent to 27 percent. African American and Latino women are also disproportionately impacted by the epidemic. African American women account for 66 percent of new AIDS cases among American women, while Latino women are five times more likely than white women to be diagnosed with AIDS. The AIDS case rate is significantly higher in the U.S. South than in other regions of the country, and the prevalence of HIV and AIDS cases in some southern communities is comparable to prevalence figures for West Africa.

More than 70 reproductive health and HIV/AIDS advocacy organizations in the U.S. have called on donors and implementing agencies to expand women's access to the female condom, which remains the only safe and effective method of woman-initiated HIV prevention currently available.

FC2 will be available in certain retail outlets. As previously announced, FHC is seeking a partner with appropriate experience to promote FC2 directly to consumers in the US.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. FC2 patents have been granted in Australia and South Africa and are pending in various other countries. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world. The Female Health Company and its partners currently market the Female Condom under FCFemale Condom®, FC2 Female Condom®, Reality®, Femidom®, Femy®, and Care®.

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

SOURCE Female Health Company


'/>"/>
SOURCE Female Health Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
5. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
6. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
9. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
10. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
11. Veto of Californias Condoms in Prisons Bill: "Politics Over Public Health," Says AHF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
(Date:6/16/2017)... 50 years ago today, the Monterey Pop Festival opened its ... San Francisco "Summer of Love."  To celebrate the anniversary, Northern ... strategic market research portals that it will begin delivering to ... Light,s "Summer of Love (For Our Customers)."  ... Northern ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on ... the Better Care Reconciliation Act. It differs significantly from the American Health Care Act, ... reconciled in committee, or the House will have to take up the Senate version ...
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus is ... among men in the U.S. and the third most common cause of cancer related death ... man in seven will be diagnosed with prostate cancer during his lifetime. Those at ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on June ... medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
Breaking Medicine News(10 mins):